Video Center

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, discusses patient and hematologist challenges in the prognosis, diagnosis and treatment strategies for AML

Published: 14 December 2016

Recent Videos: Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

video

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, talks about exciting new treatment options for CLL

video

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on intriguing data for CLL coming out of ASH 2016

video

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on which ASH AML trial results have been ...

video

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, gives his feedback on trials looking at treatment ...

video

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, discusses patient and hematologist challenges in the prognosis, ...

video

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on which ASH 2016 CLL presentations have caught ...

video

Alexander Perl, MD, discusses treatment options for AML patients

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, weighs in on AML treatment options in patients ...

video

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, on which clinical advances in CLL ...

video

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, talks about how important drug ...

video

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...

video

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML ...

video

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, explains how the CPX 351 data may impact the market and how ...

video

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, on ...

video

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, gives her view on exciting ...

video

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on how molecular testing can be used to ...

video

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, talks about how the BEAT AML master trial ...

video

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on how physicians should incorporate ofatumumab into the treatment of untreated CLL ...

video

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, speaks about the unmet medical need ...

video

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, talks about the outcomes in his ...

video

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, discusses challenges and strategies to ...

video

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, talks about the advances in CLL and the ...

video

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

Dr. O’Brien, Professor of Medicine, University of California, Irvine, shares her thoughts on the advancements in the treatment of leukemia ...

video

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, discusses how clinical pathways are being incorporated into ...

video

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, discusses CPX 351 in older high-risk patients in AML

video

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, talks about the importance of the AGIOS 221 data

video

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

Dr. O’Brien, Professor of Medicine, University of California, Irvine, discusses CLL presentations at ASH 2016

video

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on patient ...

video

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...

video

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, highlights some key data at the ASCO ...

video

Mark Levis, MD, discusses significance of the Quantum-R study

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on the ...

video

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on the ...

video

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his insights on why ...

video

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides his thoughts on the ...

video

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Eunice S. Wang, MD, discusses the Quantum First Study

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, comments on the Quantum First Study, ...

video

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...

video

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute talks about Crenolanib and its activity in ...

video

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares why sustained inhibition may be important ...

video

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares why FLT3 is important and provides ...

video

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective on immunotherapy and how ...

video

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...

video

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, discusses the application of ...

video

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...

video

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

During the ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on ...

video

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

During the 2016 ASCO meeting, Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares why specificity ...

video

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares why sustained inhibition may be important in ...

video

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

Aref Al-Kali, MD, Assistant Professor of Medicine, Division of Hematology, Mayo Clinic, shares his perspective on immunotherapy and it may ...

video

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...

video

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania talks about Crenolanib and its activity in ...

video

Alexander Perl, MD, discusses the Quantum First Study and potential implications

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, comments on the Quantum First Study, ...

video

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why sustained inhibition may be important ...

video

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why potency may be important in ...

video

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares why FLT3 is important and provides ...

video

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, highlights some key data at the ASCO ...

video

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...

video

Mark Levis, MD, on why the FLT3 target is important in AML

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides his thoughts on why ...

video

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

Mark Levis, MD, Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares his thoughts on the ...

video

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

During the ASCO meeting, Eunice S. Wang, M.D., Assistant Professor, Department of Medicine, Roswell Park Cancer Institute, shares her perspective ...

video

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

During the ASCO meeting, Alexander Perl, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, shares his perspective ...

Related Videos

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

video-image

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

video-image

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

video-image

Mark Levis, MD, on why the FLT3 target is important in AML

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

video-image

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

video-image

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the Quantum First Study

video-image

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

video-image

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

video-image

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

video-image

Alexander Perl, MD, discusses the Quantum First Study and potential implications

video-image

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

video-image

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

video-image

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

video-image

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

video-image

Mark Levis, MD, discusses significance of the Quantum-R study

video-image

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

video-image

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

video-image

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

video-image

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

video-image

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients